<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464490</url>
  </required_header>
  <id_info>
    <org_study_id>0703054</org_study_id>
    <nct_id>NCT00464490</nct_id>
  </id_info>
  <brief_title>Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts</brief_title>
  <official_title>A Prospective, Randomized, Controlled Study on the Use of Dexmedetomidine to Facilitate Extubation in Surgical Intensive-Care-Unit Patients Who Failed Previous Weaning Attempts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanical ventilation commonly is associated with patient agitation requiring sedation to
      alleviate discomfort and reduce excessive central respiratory drive. Upon recovery from acute
      respiratory failure, sedation is reduced to facilitate the withdrawal of ventilatory support.
      In some patients, abrupt reduction in sedation provokes severe agitation that causes
      catecholamine release resulting in severe hypertension, tachycardia and tachypnea. This
      requires increased sedation to bring hemodynamic and respiratory function under control.

      Dexmedetomidine is an alpha-2 receptor agonist with both sedative and analgesic properties
      that allows for the reduction in the anesthetic and analgesic requirements in the
      perioperative setting. In addition to its sedative effects, alpha-2 receptor stimulation in
      the central nervous system inhibits sympathetic activity and reduces plasma epinephrine and
      norepinephrine levels, thereby lowering both arterial blood pressure and heart rate. Because
      alpha-2 receptor stimulation does not cause respiratory depression, dexmedetomidine may
      facilitate the transition to unassisted breathing in profoundly agitated patients. The
      investigators will prospectively evaluate dexmedetomidine in 30 patients who could not be
      extubated because of agitation with hemodynamic instability and tachypnea.

      The purpose of this study is to test if a larger prospective randomized controlled pilot
      study can show that dexmedetomidine facilitates weaning and extubation in patients who have
      failed previous attempts because of agitation and hyperdynamic cardiopulmonary response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty patients who are admitted to the surgical intensive care unit (ICU) at San Francisco
      General Hospital will be referred to the investigators for enrollment into a prospective,
      unblinded, randomized study of dexmedetomidine. Each patient will be considered by the
      critical care team as a suitable candidate for weaning and extubation based on inclusion/
      exclusion criteria. Pregnant patients will not be enrolled and this will be determined by a
      negative urine or serum pregnancy test from admission. If none is available a pregnancy test
      will be performed prior to enrollment. Patients considered difficult to wean will be based on
      the following criteria:

      Eligible patients will be randomized to either the control arm or the dexmedetomidine arm in
      a 1:1 ratio by using sealed envelopes.

      Patient randomized to the control arm will be extubated per standard hospital protocol. This
      arm of the study will be observational and these patients will be extubated by the attending
      physician for that patient whenever they are hemodynamically stable enough to tolerate
      another weaning trial. The study team will collect the same data points for the control arm
      as in the dexmedetomidine arm. This includes ABGs, heart rate, mean blood pressure,
      respiratory rate and RASS scores (see description below of data points and collection time
      points.) Arterial blood gases will be drawn for the control arm of the study.

      Patients on the dexmedetomidine arm will be started on dexmedetomidine at either 0.5
      mcg/kg/hr or 0.7 mcg/kg/hr 1 hour prior to extubation. The drug calculation was based upon an
      average taken between the patient's measured and predicted body weight. Background sedation
      will be generally facilitated with lorazepam, midazolam or propofol, while analgesia will be
      maintained with either fentanyl or hydromorphine. After starting dexmedetomidine background
      sedation and analgesia will be titrated down and discontinued if possible. Analgesia levels
      also will be reduced if tolerated. Dexmedetomidine will be titrated according to blood
      pressure, RASS and heart rate response and the dose will be lowered only after sedation is
      discontinued or markedly reduced. Aerosolized lidocaine (20 mg) therapy will be initiated
      prior to the weaning trial to prevent excessive coughing in all patients.

      Shortly after the dexmedetomidine infusion is started, PSV will be commenced at 5 cm H2O
      above 5 cm H2O of continuous positive airway pressure (CPAP). Patients will be weaned to CPAP
      and evaluated for extubation.

      1.) Arterial blood gases will be obtained in all patients with an arterial line at three
      points in time: just prior to dexmedetomidine infusion, during the CPAP trial, and
      approximately 30 minutes after extubation.

      3.) Heart rate, mean blood pressure, RASS, and respiratory rate will be collected at fifteen
      minute intervals 1 hour prior to dexmedetomidine infusion, during the 1 hour infusion of
      dexmedetomidine prior to the extubation then 5, 15, 30, 45, 60, 90 and 120 minutes after
      extubation for a total of 4 hours of data collection.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of eligible participants
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical Ventilation Time</measure>
    <time_frame>time from first weaning attempt to successful extubation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Intubation; Difficult</condition>
  <condition>Respiration Disorders</condition>
  <arm_group>
    <arm_group_label>Standard Hospital Ventilation Weaning Protocol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control. Hospital weaning protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine for Extubation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedomidine infusion to facilitate extubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.</description>
    <arm_group_label>Dexmedetomidine for Extubation</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age less than 70 years old

          2. Normothermia (36.5 degrees centigrade)

          3. Normal sinus rhythm

          4. Hemodynamically stable (systolic blood pressure [SBP] &gt; 110 mmHg)

          5. Ejection fraction (EF) &gt; 40%/absence of congestive heart failure (CHF)

          6. Cardiac index &gt; 2.5 L/min/m2

          7. Minimal inotropic support (&lt; 3 mcg/kg/min dobutamine)

          8. Adequate coagulation profile

          9. Adequate urine output (&gt; 100 ml/hr)

         10. Primary service and critical care physician agreement

        Exclusion Criteria:

          1. Prior use of clonidine or alpha-antagonists

          2. Prior history of intravenous drug abuse (IVDA) or alcohol abuse (ETOH)

          3. Evidence of heart block

          4. Difficulty with oxygenation/ventilation

          5. Renal or hepatic insufficiency

          6. Pregnant (positive urine or serum pregnancy test upon admission)

          7. Patient received dexmedetomidine &gt; 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julin F Tang, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <results_first_submitted>October 25, 2014</results_first_submitted>
  <results_first_submitted_qc>October 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2014</results_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weaning</keyword>
  <keyword>Extuvation</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total accrual reached 42 of the planned 60; unanticipated common usage of Dexmedetomidine led to difficulty recruiting intubated/sedated patients who had not used it within protocol-specified period prior to enrollment. Also, some providers were not willing to allow patient assignment to the control arm given the popular usage of the drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine for Extubation (DG)</title>
          <description>Dexmedomidine infusion to facilitate extubation
Dexmedetomidine: Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine titrated according to blood pressure, RASS and heart rate response and the dose lowered only after sedation was discontinued or markedly reduced.</description>
        </group>
        <group group_id="P2">
          <title>Standard Hospital Protocol (CG)</title>
          <description>Control. Standard hospital weaning protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine for Extubation (DG)</title>
          <description>Dexmedomidine infusion to facilitate extubation
Dexmedetomidine: Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine titrated according to blood pressure, RASS and heart rate response and the dose lowered only after sedation was discontinued or markedly reduced.</description>
        </group>
        <group group_id="B2">
          <title>Standard Hospital Protocol (CG)</title>
          <description>Control. Standard hospital weaning protocol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ramsay Sedation Scale (RSS)</title>
          <description>The RSS defines the conscious state from a level 1: the patient is anxious, agitated or restless, through the continuum of sedation to a level 6: the patient is completely unresponsive.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="1.2"/>
                    <measurement group_id="B2" value="2.1" spread="1.1"/>
                    <measurement group_id="B3" value="3" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mechanical Ventilation Time</title>
        <time_frame>time from first weaning attempt to successful extubation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine for Extubation (DG)</title>
            <description>Dexmedomidine infusion to facilitate extubation
Dexmedetomidine: Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine titrated according to blood pressure, RASS and heart rate response and the dose lowered only after sedation was discontinued or markedly reduced.</description>
          </group>
          <group group_id="O2">
            <title>Standard Hospital Protocol (CG)</title>
            <description>Control. Standard hospital weaning protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanical Ventilation Time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="139.4"/>
                    <measurement group_id="O2" value="203.9" spread="150.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H(0): Ventilator time (DG) = Ventilator time (CG)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>P-value &lt;0.05 was considered significant</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hour pre- to 2 hours post-extubation</time_frame>
      <desc>We monitored for adverse events associated with the study intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine for Extubation (DG)</title>
          <description>Dexmedomidine infusion to facilitate extubation
Dexmedetomidine: Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine titrated according to blood pressure, RASS and heart rate response and the dose lowered only after sedation was discontinued or markedly reduced.</description>
        </group>
        <group group_id="E2">
          <title>Standard Hospital Protocol (CG)</title>
          <description>Control. Hospital weaning per standard protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lower than anticipated enrollment due to unwillingness of providers to assign patients to the control group led to smaller-than-planned samples for analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Julin F. Tang, MD, MS</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-206-5274</phone>
      <email>tangj@anesthesia.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

